Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after the company cut its 2025 forecasts.

Novo Nordisk A/S shares gained on expectations that competition for its blockbuster obesity shot Wegovy will subside later this year.

Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand in the U.S. Karsten Munk Knudsen, Novo Nordisk’s chief financial officer, told Fortune the company is well-placed to handle the geopolitical upheaval that rocked global business in March and April.

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish drugmaker Novo Nordisk that should expand access to its in-demand GLP-1 at the expense of Eli Lilly’s.

Novo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and diabetes drugs.

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)’s share was trading at $67.

Within six months, the drug reduced the risk of cardiovascular death by 50 and cut the risk of needing urgent treatment due to heart failure.

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.